KA2507   Click here for help

GtoPdb Ligand ID: 12269

Compound class: Synthetic organic
Comment: KA2507 ia a clinical stage, selective and orally bioavailable HDAC6 inhibitor, that was designed for potential to treat advanced solid malignancies [1]. This compound produces a direct antitumour effect, and it promotes an antitumour immune response.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 104.13
Molecular weight 322.12
XLogP 0.92
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES ONC(=O)c1ccc(cc1)CN(c1cnccn1)c1cnccn1
Isomeric SMILES c1cc(ccc1CN(c1nccnc1)c1nccnc1)C(=O)NO
InChI InChI=1S/C16H14N6O2/c23-16(21-24)13-3-1-12(2-4-13)11-22(14-9-17-5-7-19-14)15-10-18-6-8-20-15/h1-10,24H,11H2,(H,21,23)
InChI Key LXHMTDHBMRZSHJ-UHFFFAOYSA-N
References
1. Tsimberidou AM, Beer PA, Cartwright CA, Haymaker C, Vo HH, Kiany S, Cecil ARL, Dow J, Haque K, Silva FA et al.. (2021)
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors.
Clin Cancer Res, 27 (13): 3584-3594. [PMID:33947698]